KIR3DL1 and myeloid neoplasm: To determine whether HSC grafts with non-expressed KIR3DL1 increase relapse incidence after hHSCT in patients with myeloid malignancies, univariate and multivariate analyses were performed considering confounding factors, such as age, diseases, DRI, status at the time of transplantation (first complete response (CR) versus subsequent CR versus lack of CR), and conditioning.